Rebecca S. Eisenberg – Pharma's Nonobvious Problem
Overview: There are lots of problems relating to patents regarding pharmaceuticals. Many of the compounds are substantial similar to other patents making prior art review a questionable standard for patents.
Highlights: The problem is that the pharmaceutical industry has a lot of obvious patents. There is an incentive to wait to release innovation until a competing drug is about to lose protection.
Brian's response: dizzying array of issues related to pharmaceutical patents, I look forward to reading the final article. This talk was very interesting but a bit scattered.
Interesting note(I learned a new term): Evergreen patent = pharmaceutical company tactics to extend patent protections. (Patently Abusive).
